SEARCH

SEARCH BY CITATION

References

  • 1
    Rothenberg ME, Zimmermann N, Mishra A, Brandt E, Birkenberger LA, Hogan SP et al. Chemokines and chemokine receptors: their role in allergic airway disease. J Clin Immunol 1999;19:250265.
  • 2
    Green RH, Brightling CE, Mckenna S, Hargadon B, Parker D, Bradding P et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:17151721.
  • 3
    Humbles AA, Lloyd CM, Mcmillan SJ, Friend DS, Xanthou G, Mckenna EE et al. A critical role for eosinophils in allergic airways remodeling. Science 2004;305:17761779.
  • 4
    Lee JJ, Dimina D, Macias MP, Ochkur SI, Mcgarry MP, O’Neill KR et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 2004;305:17731776.
  • 5
    Schleimer RP, Fox CC, Naclerio RM, Plaut M, Creticos PS, Togias AG et al. Role of human basophils and mast cells in the pathogenesis of allergic diseases. J Allergy Clin Immunol 1985;76:369374.
  • 6
    Fujitani Y, Kanaoka Y, Aritake K, Uodome N, Okazaki-Hatake K, Urade Y. Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice. J Immunol 2002;168:443449.
  • 7
    Almishri W, Cossette C, Rokach J, Martin JG, Hamid Q, Powell W. Effects of prostaglandin D2, 15-deoxy-delta12,14-prostaglandin J2, and selective DP1 and DP2 receptor agonists on pulmonary infiltration of eosinophils in Brown Norway rats. J Pharmacol Exp Ther 2005;313:6469.
  • 8
    Shiraishi Y, Asano K, Nakajima T, Oguma T, Suzuki Y, Shiomi T et al. Prostaglandin D2-induced eosinophilic airway inflammation is mediated by CRTH2 receptor. J Pharmacol Exp Ther 2005;312:954960.
  • 9
    Spik I, Brenuchon C, Angeli V, Staumont D, Fleury S, Capron M et al. Activation of the prostaglandin D2 receptor DP2/CRTH2 increases allergic inflammation in mouse. J Immunol 2005;174:37033708.
  • 10
    Kostenis E, Ulven T. Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol Med 2006;12:148158.
  • 11
    Hamid-Bloomfield S, Payne AN, Petrovic AA, Whittle BJ. The role of prostanoid TP- and DP-receptors in the bronchoconstrictor effect of inhaled PGD2 in anaesthetized guinea-pigs: effect of the DP-antagonist BW A868C. Br J Pharmacol 1990;100:761766.
  • 12
    Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001;193:255261.
  • 13
    Heinemann A, Schuligoi R, Sabroe I, Hartnell A, Peskar BA. Delta12-prostaglandin J2, a plasma metabolite of prostaglandin D2, causes eosinophil mobilization from the bone marrow and primes eosinophils for chemotaxis. J Immunol 2003;170:47524758.
  • 14
    Sugimoto H, Shichijo M, Iino T, Manabe Y, Watanabe A, Shimazaki M et al. An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. J Pharmacol Exp Ther 2003;305:347352.
  • 15
    Bohm E, Sturm GJ, Weiglhofer I, Sandig H, Shichijo M, Mcnamee A et al. 11- Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils. J Biol Chem 2004;279:76637670.
  • 16
    Ulven T, Kostenis E. Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist. J Med Chem 2005;48:897900.
  • 17
    Mathiesen JM, Christopoulos A, Ulven T, Royer J, Campillo M, Heinemann A et al. On the mechanism of interaction of potent, surmountable and insurmountable antagonists with the prostaglandin D2 receptor CRTH2. Mol Pharmacol 2006;69:14411453.
  • 18
    Kostenis E, Martini L, Ellis J, Waldhoer M, Heydorn A, Rosenkilde MM et al. A highly conserved glycine within linker I and the extreme C terminus of G protein alpha subunits interact cooperatively in switching G protein-coupled receptor- to-effector specificity. J Pharmacol Exp Ther 2005;313:7887.
  • 19
    Palframan RT, Collins PD, Williams TJ, Rankin SM. Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow. Blood 1998;91:22402248.
  • 20
    Stubbs VE, Schratl P, Hartnell A, Williams TJ, Peskar BA, Heinemann A et al. Indomethacin causes prostaglandin D(2)-like and eotaxin-like selective responses in eosinophils and basophils. J Biol Chem 2002;277:2601226020.
  • 21
    Mahmudi-Azer S, Downey GP, Moqbel R. Translocation of the tetraspanin CD63 in association with human eosinophil mediator release. Blood 2002;99:40394047.
  • 22
    Hartnell A, Heinemann A, Conroy DM, Wait R, Sturm GJ, Caversaccio M et al. Identification of selective basophil chemoattractants in human nasal polyps as insulin-like growth factor-1 and insulin-like growth factor-2. J Immunol 2004;173:64486457.
  • 23
    Ney P, Schror K. PGD2 and its mimetic ZK 110.841 are potent inhibitors of receptor-mediated activation of human neutrophils. Eicosanoids 1991;4:2128.
  • 24
    Schratl P, Sturm EM, Royer JF, Sturm GJ, Lippe IT, Peskar BA et al. Hierarchy of eosinophil chemoattractants: role of p38 mitogen-activated protein kinase. Eur J Immunol 2006;36:24012409.